In Celexir’s body-recomposition toolkit, Ipamorelin is positioned for patients who need recovery, lean-mass support, and fat reduction without undue endocrine noise. Clinically, it’s used as a selective GH-pathway adjunct inside programs that also emphasize sleep, progressive resistance training, nutrition, and inflammation control.
How it works: Ipamorelin is a selective ghrelin (GHS-R1a) receptor agonist that triggers natural, pulsatile GH release with minimal off-target hormone effects (notably low prolactin/cortisol spillover compared with older GHRPs). This selectivity has been documented in pharmacology studies and reviews of growth-hormone secretagogues.
Evidence & diligence: Foundational work showed Ipamorelin increased GH without raising ACTH/cortisol, unlike GHRP-2/6—supporting its “clean” profile for recovery and body-comp goals; modern summaries continue to describe ghrelin-pathway agonists as targeted GH secretagogues useful in selected clinical contexts. Athletes should note WADA prohibits GHS (including Ipamorelin). Frame use as part of a supervised program with objective tracking (strength/lean mass, recovery metrics, body fat).
Celexir delivery & specs: catalog guidance 200–300 mcg, 1–2× daily; >98% purity; 2–8 °C storage; injectable penwith CoA/MSDS to keep dosing consistent from warehouse to administration. Integrate with nutrition periodization and sleep/circadian alignment to translate GH pulses into durable performance and composition gains.